BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange.


We unite AI with cutting-edge science to discover life-changing medicines.

Through the combined capabilities of its AI platform, its scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods.

The Benevolent Platform™ powers BenevolentAI’s in-house drug pipeline and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Our pipeline

Reports and presentations

Date and title 21 Sep 2023
Interim results for the six months ended 30 June 2023
Presentation View
Webcast Watch

All reports and presentations


All announcements

Annual Report

Annual Report 2022

Financial calendar

September 2023
Interim Results for the six months ended 30 June 2023

Full calendar

Investors - Email Alerts.jpg


Get alerts for our announcements

Investor events, conference attendance and annual reporting.

Sign up